ERBB2 and gastroesophageal junction adenocarcinoma: An open label, international, phase 3, randomized-controlled trial (ToGA) enrolled 594 HER2-positive gastric or gastroesophageal junction adenocarcinoma patients indicated that compared with chemotherapy alone, trastuzumab (a monoclonal antibody against HER2) plus chemotherapy significantly improved patients survival (mOS: 11.1 moths vs 13.8 moths, p = 0.0046).